Correlation between serum prostate-specific antigen and cancer volume in prostate glands of different sizes.
暂无分享,去创建一个
W. Catalona | G. Carvalhal | Donghui Kan | S. Loeb | K. Roehl | Dana M Mondo | Saima Daudi
[1] Peter H Gann,et al. Prostate specific antigen best practice statement: 2009 update. , 2009, The Journal of urology.
[2] A. Jemal,et al. Cancer Statistics, 2009 , 2009, CA: a cancer journal for clinicians.
[3] R. Nelson,et al. The impact of prostate gland weight in robot assisted laparoscopic radical prostatectomy. , 2008, The Journal of urology.
[4] R. Miralbell,et al. Recent trends in prostate cancer mortality show a continuous decrease in several countries , 2008, International journal of cancer.
[5] L. Ferrucci,et al. Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. , 2006, Journal of the National Cancer Institute.
[6] W. Catalona,et al. Pathological characteristics of prostate cancer detected through prostate specific antigen based screening. , 2006, The Journal of urology.
[7] Liang Cheng,et al. Maximum tumor diameter is an independent predictor of prostate-specific antigen recurrence in prostate cancer , 2005, Modern Pathology.
[8] William J Catalona,et al. The era of serum prostate specific antigen as a marker for biopsy of the prostate and detecting prostate cancer is now over in the USA , 2004, BJU international.
[9] Rosalie Nolley,et al. The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years? , 2004, The Journal of urology.
[10] Ming-Hui Chen,et al. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. , 2004, The New England journal of medicine.
[11] P. Humphrey,et al. Prostate-specific antigen cutoff of 2.6 ng/mL for prostate cancer screening is associated with favorable pathologic tumor features. , 2002, Urology.
[12] T. Stamey. Preoperative serum prostate-specific antigen (PSA) below 10 microg/l predicts neither the presence of prostate cancer nor the rate of postoperative PSA failure. , 2001, Clinical chemistry.
[13] P. Humphrey,et al. Visual estimate of the percentage of carcinoma is an independent predictor of prostate carcinoma recurrence after radical prostatectomy , 2000, Cancer.
[14] T. Stamey,et al. Assessment of morphometric measurements of prostate carcinoma volume , 2000, Cancer.
[15] M E Hammond,et al. Updated protocol for the examination of specimens from patients with carcinomas of the prostate gland: a basis for checklists. Cancer Committee. , 2000, Archives of pathology & laboratory medicine.
[16] T. Stamey,et al. Biological determinants of cancer progression in men with prostate cancer. , 1999, JAMA.
[17] P. Humphrey,et al. Percentage of free serum prostate-specific antigen as a predictor of pathologic features of prostate cancer in a screening population. , 1998, Urology.
[18] R T Vollmer,et al. Percentage carcinoma as a measure of prostatic tumor size in radical prostatectomy tissues. , 1997, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.
[19] D. Bostwick,et al. Recommendations for the reporting of resected prostate carcinomas , 1997, Human pathology.
[20] D. Bostwick,et al. Recommendations for the reporting of resected prostate carcinomas. Association of Directors of Anatomic and Surgical Pathology. , 1996, American journal of clinical pathology.
[21] P. Troncoso,et al. Tumor volume and prostate specific antigen: implications for early detection and defining a window of curability. , 1995, The Journal of urology.
[22] T. Stamey,et al. The pathological features and prognosis of prostate cancer detectable with current diagnostic tests. , 1994, The Journal of urology.
[23] P. Walsh,et al. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. , 1994, JAMA.
[24] A W Partin,et al. Is tumor volume an independent predictor of progression following radical prostatectomy? A multivariate analysis of 185 clinical stage B adenocarcinomas of the prostate with 5 years of followup. , 1993, The Journal of urology.
[25] A S Whittemore,et al. Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer , 1993, Cancer.
[26] A. Rademaker,et al. Re: Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. , 1990, The Journal of urology.
[27] T. Stamey,et al. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients. , 1989, The Journal of urology.
[28] K. E. Corrigan,et al. Detection of concealed thyroid disease by tracer technique. , 1953, Journal of the American Medical Association.
[29] O. Brawley,et al. Cancer screening in the United States, 2009: A review of current American Cancer Society guidelines and issues in cancer screening , 2009, CA: a cancer journal for clinicians.
[30] William J Catalona,et al. Accuracy of prostate weight estimation by digital rectal examination versus transrectal ultrasonography. , 2005, The Journal of urology.
[31] A. Hoznek,et al. Prognostic significance of tumor volume after radical prostatectomy: a multivariate analysis of pathological prognostic factors. , 2003, European urology.
[32] T. Stamey,et al. Limitations of serum prostate specific antigen in predicting peripheral and transition zone cancer volumes as measured by correlation coefficients. , 1996, The Journal of urology.